PODD - Earnings call transcript Q4 2017

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Fourth Quarter and Full Year of 2017 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Deborah Gordon, Vice President, Investor Relations and Corporate Communications.

Deborah Gordon

Brian. you, Thank thank quarter and joining for us Good earnings you call. fourth XXXX our afternoon for

and of on available full-year discussing XXXX Joining are Officer; is press Shacey also our Officer. Petrovic, Senior me our Executive President first The fourth President Chief will be today our Vice call and and Patrick replay Sullivan, of Chief Chief Operating and archived and quarter and this Levitz, the quarter section and Michael IR Financial Chairman in website. our website, release XXXX results guidance Officer;

Before Safe actual factors you referenced financial and With changes during known earnings the we on basis. made to and that, in in those from different results Such to fourth unless be a begin, results call the Pat. I turn certain Insulet involve will our I stated, over include cause would and with Also unknown like be quarter by materially our risks may to and the statement, year-over-year by percentage such future call statements. forward-looking release, regarding SEC. that any dollar otherwise inform and course uncertainties implied this of filings Harbor may company's be in statements will the commentary all that

Patrick Sullivan

plan performance on XXXX simply provide initiatives for as everyone will XXXX. QX up financial Thank We’ll results call and well with XXXX provide the guidance. off and welcome FDA. Omnipod significant list Part Mike our details system. was coverage you, of guidance and year one was to business XXXX gaining company questions. the spectacular will and call. good accomplishments. a highlights I’ll start generation for then on and D our US strong in and submitted progress. XXXX our with then our an call product of a to we financial of and XXXX Deb we base. implementing Acton, QX for open we DASH, our of delivered afternoon, our go year Medicare customer Insulet’s on to Europe very CMS conference the R&D full XX% the follow worldwide commercial our over a and direct next Number growth fourth an We're update quarter details the including for overview in the year Number Shacey manufacturing and as results, in and two, on my Massachusetts QX plant broke and platform ground

States, roughly United third coverage who have Medicare Medicaid the growth January CMS and launching priorities Part provide accomplishments to on product the were The DASH have for this program. off The first I'll year great Omnipod for Part only sponsors, a transitioning Medicare Omnipod pathway On clarifying our or our the to X, Omnipod. the importantly are news XXXX, through namely fuel and not four for CMS XXX,XXX now the the the into with coverage our X that Type but a the US coverage D are business strategy. future, our for Omnipod. our implementing individuals D products in securing as under the issued direct access permitted to with European Part D platform, Medicare of start the Drug in diabetes distribution manufacturing market such now Prescription will sponsors guidance coverage XXXX

Omnipod for or no clear channel Omnipod. prescription transitioning Securing They since plans and those Medicare with are continue D will also to the in prescription access a access be provides coverage age who experience, in for a a pharmacy as sustaining since Medicare beneficiaries. coverage since longer competitive Medicare differentiator Medicaid opportunity pathway to to through users will better now easier patient the physicians the with into Our channel Medicare their to paying monumental Medicare the a us Part drug out life same the less users a faced D advantage pocket is benefit accomplishment And pharmacy use they provide a with will be most their Part do Medicare it’s they CMS channel guidance. of direct that coverage is prescribe secure simpler to The of have coverage to will will tremendous to our Insulet. channel. our for to and in Achieving the Medicaid able drugs. and provide state alternative. this a attractive Omnipod Omnipod follow Omnipod it

those Medicaid, will on a finally the individuals choice. population, Omnipod become particularly For pediatric

benefits and year this the exception of year service Part Omnipod community. D of is placing in meantime, with will sponsors. D XXXX huge current diabetes our team Omnipod Part customers focus team Medicare coverage Achieving formulary expect physicians to In to access market begin this the during the to a win Medicare customer D for the work process. Medicare will on patients, gain We coverage the the Part access and our our on

mobile update the an month, platform. FDA we submitted the Last on a to for Omnipod DASH DASH. our next system, Next XXX(k) generation

Horizon innovation mobile very what in this of and platform excited and the clearance, is means launch dependent the and of all including state-of-the-art customers. this Insulet DASH U-XXX and FDA innovation DASH our is it are about year. course our programs pipeline, our upon for The second half expect of Automated we U-XXX We of for with potential significant Control of which the Glucose System. Lilly

Austria, Now Advanced with also thrilled of execution. we're on X. the the distribution team knowledge and system the attended building Omnipod track Last in in July Europe. incredibly ATTD of our healthcare Insulet visitors as our an our first our turning of on had with the days and at on at exhibition I ground level and Treatment the in providers, many business, with commercial several hall including a in and we're the successful our or of large We Diabetes of event, market where Vienna, direct number transitioning booth to advisory very board. team’s and European week, the I European physician exhibited am busy Europe impressed European Technologies exceptional meetings to with experience time transition meeting partners our Europe. of the for the in I'm the we

a vast an latest XX,XXX patients International this customer of Insulet also The by end real on expect conducted and the customer review in clinical focused at experience XX,XXX in results data an world last estimated with year and we international majority pipeline. of We to Europe continue year. symposium The a Horizon XXX researchers participants, attended on to progress, of from was base and the a innovation base at Europe. nearly grow Omnipod

to truly experience level best the in this transition will as the forward and transition distribution describe and profile half we on necessary we for Europe, deliver has possible shortly. transition required distribution to While successfully talent our work to financial is customers of year, to improves This ensure I'm a direct business X. the appreciate significantly to and as July second our team the looking opportunity Mike of our customer and the huge in continuity the care direct this of skills European

Now, manufacturing. turning to

to reliable gross made scrap, to Massachusetts on the and with drive performance facility have track which and drive in in new margins in to XX% will less clear increased begin sustained a production of line and of state and XXXX, manufacturing new improvements in global significant manufacturing for production of a across XXXX. and also This headcount superior We sizable business the daily we as very outstanding site We're have our supply sight serve continues in our improvements our products. quality volume to while our delivering chain continue production operations margin headquarters. art

start this we success Operational will out key expect capacity a the trajectory. We redundancy growth facility production our automation excellence the to and second later new who increased equipment what it's factor The is do and in and at will core for and facility this we XXXX. support business. provide install build of year source significant are and early to the

momentum. million most range. $X our in was across guidance Finally, International let's XX%. XX% results, growing our a our million, or million, $XXX year-over-year and delivered which to US million, exceeded strong above $XXX turn growing business revenue XX% than the and strong million, We recent performance with midpoint Omnipod was outstanding and growing of more of performance our XXXX XX Omnipod and delivery growth revenue financial evidenced $XXX guidance was drug XX%.

accomplishments year gross from last year. margin than of improvement year Our year a was an and full was of XXX performance. more The points XXXX basis significant XX%,

for During growth the foundation profitability. laid year, further we the and

very year for exciting built we momentum positive up the of company. result to another in is this shaping a be the XXXX, As year

is billion gross very market The through are pipeline for with of and margin and XXXX our We beyond growth our XX% targets in expansion. $X XXXX significant innovation revenue, rich above opportunities geographic confident further profitability. in future

us. are Mike. delivering on priorities innovation focus that, Michael? with for We bright excited of proud XXXX, turn our call worldwide And superior and and in shareholders. I’ll the team's customers exceptional ahead extraordinary execution our and to to about of our on returns I'm their focusing future over the performance the XXXX

Michael Levitz

the momentum from guidance to and you of for then markets, about US Thank now with exceeded customer excitement by base strong Pat. XXXX. to We stated of growing quarter through the year XX% very year France. revenue from across and revenue fourth seeing positive year-over-year the coming XXXX we our Omnipod indicators already million. Pat’s of beat due discuss first the remainder fourth XXXX will coming of the and quarter you, with of our quarter full guidance. beat report due continued $X in in our to I pleased including Omnipod incredible international the walk million results We're $XXX.X had strength echo our two-thirds we're growth midpoint and I

Pat years, just points This we've to is of to discipline the unfavorable mix supply Our growing. result a growth execution increased chain drive offset part international we in significant primarily XX% improvements and gross by to as over distributor seen due outlined, made sales. the have XXX that from efficiency, our and in mid-XX% margin XX.X%. margin the to incredible improvements In in and gross quality team's range a last both growth and few operations manufacturing growing from just faster basis

we gross in and begins even We cost approaching XXXX manufacturing before considerable this goal are toward targeting headway year. to make next that US margin year, lower expect XX%

the $XXX ended million, $XXX objectives. increased million the the achieving quarter over million Our and end year investments convertible $XX XXXX proceeds our we of up cash XX the our In in us sheet, proceeds existing notes to we notes on line and operating million in in and expectation to was loss the used repurchase a million. balance with net for over at and to fourth than million higher well We XXXX. of more expenses result compared issued operating subsequently small coupon XXX with November, in $XXX positions with it net from

generated XX operations. million During from our $XX operations, notably over a US significant on we most growth support capital in prior spent investment XXXX, manufacturing business, the and cash of improvement We've in for to million chain years. our from expenditures supply

XXXX expenditures in XXXX to pod development to We're capital we very in said, growth our production our position is strategic now will as as we support our outlook. of opportunities. as I expect We investments strong valuable financial which in operations you complete organic of XXXX. on new from increase schedule Pat walk US XXXX begin our with through early our pleased make

For revenue in million, XX% total the year, range of of we $XXX XX%. to million $XXX expect growth to full the representing

representing XX%. growth revenue of growth the describe will $XXX in exceptional which First, $XXX Omnipod the range continued international $XXX customer base, we reflects of in to XX% strong be This This XX%. in XXXX, million, million by growth $XXX of XX% US Omnipod to representing to expect US million expect of we growth three Shacey In primarily to will factors. revenue range shortly. million, driven our

July we after existing of in approximately pricing more Europe, direct capturing value operations end our up X. from historic distributor of XX% assumed the pricing First, user

in in XXXX. in adoption be continued the XXXX to the the impact Second, operations. our will in direct significant third, through base in full existing priority transition increase growth continuity even customer markets Omnipod top customer as year of And our

XX% of to from in decrease we reflects the decline delivery, $XX the $XX revenue drug of million, This current million a For range representing to XX%. forecast Amgen. expect

$XX the of quarter million revenue level, million million, a range the first XXXX, XX%. in in for XX% of million, XX% $XX.X to representing Now, of to expect expect growth total $XXX representing $XXX the we to XX%. Omnipod we of product to range US of At line growth

to XX% range that $XX decline note for our to We new delivery our accounting We P&L. million the XXXX, million, million expect XX%. drug have of international Omnipod adoption the Please presented growth not $XX are million. revenue in which we in material trends. reflects of of do X representing related our a expect million, a million standards X $XX.X And range to impact to of in on this $XX expect guidance representing the of to prospectively financial effective

Specifically, $X the million the year. throughout XXXX our adoption full approximately revenue in of over revenue of spread by $X delivery and XXXX these than X% international half of $X guidance year non-recurring the rules spread less increased evenly for drug first million, or million including

$X approximately the million, evenly quarter, rules adoption international these split delivery. drug between by guidance the For first and of increased

gross basis will to significantly, XXXX, operational again full and XX%, continued basis XXXX gross we margin, operations assuming gross direct XXX expect impact to in following our driven of up partial European margin increase July by points year points of to expansion X. improvements XX% XXX margin moving year over Now the

we margin of rate points increase run As expect beginning an basis X. annual XXX July we previously, stated approximately

be gross our production such, to continue Europe half the in of United revenue including in growth to XX% XXXX. in and our XX% to consolidated half in-house first goals, profitability to for early investments incremental in of expect establish margin to second and and our to the begin will the As in to we in XXXX. increasing the invest we direct achieve business, operations States manufacturing To XX% XX% both in mid-year year XXXX

the innovation expansion We as expect XX%, our infrastructure. with includes period $X Omnipod Europe the European also the take operating investments exciting the and full consistent Please investment of requiring X% in sales expenses commissions the increase benefit. of up million. in by Outside demand to of a that decision that our of new revenue pipeline seeing expenses the year continued meet XXXX cost relatively to Part is our increase well to to adoption expenses will even growing but US percentage the as manufacturing, new and remain commercial to operating in our as accounting our capitalization of we're in coverable teams in XXXX be of The the advantage to that XXXX expenses note will standards, amortized rules to benefit. be adoption CMS’s of D impacted over these reduce of drug approximately under by establish

operations rate stated, to we million European previously ongoing million, of expenses the guidance. require As expect $XX in transition are XXXX included run stated European direct which the $XX will to

we transition, primarily million expect operations. in associated We first this with the establish our $X also of non-recurring costs including certain to $X as XXXX half million

with terminations a distributor European pay to our them. on we’ll addition, In fee our contract based

we assumed be not the financial the fee the it While material our agreement, do after our as based P&L the of amortized to on we impact the it trends significantly period direct vary have could determined operations a amount will benefit. will year on on over multi-year be terms of over the and expect

profit make to the direct Finally, pivot we full the range. begin the digit to investments at expect European X. This margins year this reflects single the XXXX before of European July start operating in beginning revenues infrastructure with year percentage low operating

in second we first and our the was growth operating half to of strong that growth expansion for growth will yet, of expect looks the and over development the fulfilling XXXX income getting in in we're investments to summary, in In to we XXX margin a Shacey. history just in XXXX such, over half for sequentially basis deliver at most and points the and tremendous As beyond where further exciting positive company's XXXX call earnings Insulet US operating with accelerate the the be and I year increase line, gross top and Europe XXXX. time will even manufacturing turn now margins first the and started. in

Shacey Petrovic

share cover And with off global shared discuss the year will we have to terrific take our then team’s our us we including we Pat Building accomplishments ahead. our I about I what start Mike customer and to growing you, in I'll on imperatives enthusiasm strategic Mike. ended XXXX base, strong XXXX in XXXX. the momentum Thanks, and for expect are and the XXXX. where where in a

Our commercial revenue driving and growth. strategies are clearly tremendous customer base

As of Omnipod’s the is because a of revenue predictor the revenue reminder, customer best growth. recurring model, base growth

and base active XXX,XXX ended between half our customer total third-party a the distributors. an with US and XXX,XXX markets. of because our increase base customer approximately and XX% estimated global approximated company US strong majority Our XXXX, revenue customer represents international our XX% the estimate, and customer of XX% our users, of the XX% year-over-year base By end base We base international global is by in international an go XXXX our our over grew base and XX%. which drove growth. through of mix We US approximately in by

positioned great our will again on in to commercial growth how momentum our this Given strength well team XXXX. is and in market, we robust drive the capitalize

to expect of US strong raising our customer supported awareness In base driving increasing our field deliver US, will footprint year. and XX% access, are by commercial investments paying the market XX% broader grow We and off approximately growth. team, execution this our in the will to continue

our efficient, incredible up to approximately As drive coverage you ensure know, medium and to initiatives. will class with for Medicaid payers. and customer opportunity by but success pharmacy be our Two existing year. the global growth strategic our year's This successfully channel typically there In win and who channel There One base over for access through already this term, for for benefits. widespread access starting XX%. needs. easier for continue an the key subject long a the adjustment, customer international grow secure getting our of business The Medicare customers. a are a win and XXXX year Three growing this grow is receive that is new is and benefits innovative technology existing expect work provides physicians portion potential reimbursement QX is as period transition mobile care of through overall also development may XXXX, no year. Omnipod coupled pharmacy significantly time of community of their our a hurdles our business pharmacy Omnipod focus the our experience their treat be Medicare customers mission and channel our Medicare, is access. through Naturally, of our to with overall establish formulary pharmacy D in US we revenue our offer percentage choose where noted, the customers coverage it's hear a XXXX, commercially to our that focused we in Coverage and to will are diabetes the challenges transition benefits A and Europe DME half users world patients successfully including secure which product Europe, continuity channel, the a our pipeline, of the to our great next is our the base policies Omnipod beneficiaries this the for new the the our now on three has when is XX% support growth now supplies. Omnipod traditional teams at for customers, less and deductibles. will but year's customer pods, plan our the direct which our for broader in suits base company. are margin provides insulin Medicare Starting expand coverage to patients through this is clearly large is best their stand will pharmacy model, on an Pat option and the and of a for less approximately them in rich this to and transition XX%, and We there pharmacy for win advantages. of so and and of more strong with launch growing their diabetes platform. true their a burdensome device change similar clinics will access, of the to a our and covered channel second start time Between business Medicare improved included driven to is of It's European work innovative and commercial to pharmacy who to a with to from In business. Omnipod, commercial Part users our gaining sponsors operations differentiated, this longer turnaround of typically DASH system and our in our big gross most fraction win. through coverage is

top We top of also D negotiating relatively the sponsors small a benefit with Part planned XX%. XX% approximately eight and have cover number represent three the approximately covered of life as of the Medicare

Medicare and We plans plans. low for the differentiated for and upfront on Omnipod factor time, are D guidance broad state widespread accelerate access Medicaid coverage are and are planned CMS’s currently XXXX. help Part secure provide sponsors. Medicare these of a proposition Medicaid with and the same form we in process all we strong we Omnipod’s confident these will establishing in value cost should discussions of with At access

on ease efforts. payers. stakeholders, about unlike the it and benefits technology And significant a across technology. the keen is another product so other We mobile XXX(k) in for innovation is use of clinicians FDA patients, eyes unique of and of DASH. through important our DASH this all customers, the DASH through designed DASH for of ease milestone any so our that is innovative what with of the focus and our achieved provides market. core clearance Next, last filing use. of month We At simplicity drive our with Omnipod is

for and our addition users secure display of addition payers. physicians patients, and the With caregivers their data phone mobile insights for connectivity, DASH for to Bluetooth and in mobile will apps provide

touchscreen our display well means pod modern Their the through with their sharing on a View apps patients, data their have informed and via will with benefit easy accessible controlled app. delivery Omnipod caregivers by now controlled data new and incredibly our of smartphone will also For they Omnipod be added PDM. this their

to boarding, payers the DASH DASH diabetes data. clinicians, patients’ including ability have on down by geography And Payers with this through work to access into less training membership immediate a progress data will easier outcomes our outcomes. to detailed Omnipod’s time means link launch understand limited can demographics, For to later to boards. improved patient better their behaviors patient and forward through review We’ll on and their and specific the look year. FDA as they populations Omnipod access DASH market drill data of

foundation is our innovation, DASH for Glucose programs Omnipod for Automated Our concentrated the Omnipod U-XXX and System. Horizon Control insulin future development and including U-XXX our platform

all We and on products track next years. of development few are market into this progress making the over to with substantive we're work these the introduce

pathway will world milestones sales to our with Amgen well We're our long over Neulasta as are delivery this product and revenue an the drug experience were kit. with for the to attractive the primarily their with stream reflects the Today, line, product data business that line as and share term we're currently that that physicians an generates. about year progresses. a with demonstrated we users, innovation to confident Onpro recurring insights represents it mainly development what and access payers outcomes. In to market excited critical as the will in exciting opportunity continue you our provide class on We their eager Omnipod differentiate

just exited Amgen of adoption As over US noted, fourth recently quarter of XX% doses XXXX all the sold. at Neulasta

provides with active outcomes feedback explore Omnipod’s on partners also based opportunities truly pod other have confident our adherence the remain their connected product that to offering. unique technology. therapies potential has pod we our improve believe wearable, delivery platform incorporate and discussions differentiated and will non-informed platform continue and We pharmaceutical a to and

July our Now, of we've turning the customers our X. transition our business to successful Omnipod international exciting expanding support to on European infrastructure a progress made and

of of all hitting plan our and are European a milestones very in considerable team. the We benefiting our key thorough thoughtful management and very expertise new from we're strategic

includes access, diabetes various and incredible hired amount the all importantly This functions. support deep customer market service European team experience newly within Our geographies an team and of a leaders throughout sales, commercial of other areas knowledge of community, brings continue gain partners, market a to diabetes talented seamless and transition our day this payers key insight European for business to leads market team into and the deep support dynamics. Thanks one. and prepare of on the we key

One the intermediaries, number majority have is we risk. of the is served of the we've mitigates with learnings and that contract key of to had transition reduces vast this parties which through business

addition our within in to So in markets. the major of exists of concentration the five volume Omnipod business Europe, XX%

also these We markets. have this within among concentration those further intermediaries

to drive our long are direct As and us increasingly key transition, set significant we that move of we move provide value. term our up through confident this all to distribution will meaningful stakeholders to benefits

we strength reviewed additional Omnipod through the grow, publications across evidence, the continue clinical studies to and we As peer the supporting globe. of build within

month. We publications clinical are two thrilled this announce to

who after it demonstrating year. the that Pediatric German Austrian and improved injections was daily with first multiple is published Diabetes, associated glycemic one control Omnipod adolescents The switched comparing Registry from was in Manuscript Omnipod to

in underway, studies system of United longer for second Our challenges our Vienna, very in IDE the presentations second Kingdom. to free further we two publication and diabetes. results and the our highlighted IDE there data from and in adults States, world At additional Therapeutic. type Omnipod in with in at that United were and Omnipod perform just use the Germany ATTD week, Horizon was use X setting. the are meal living time exercise continues study, data first the Horizon last published our algorithm demonstrate also Also journal, well examining examining Technology of ATTD, and Diabetes These presented real in

of benefits am a global the accomplishments. awareness building clinical strong closing, I the of are of greater and We of our community. In throughout team's technology diabetes generating body proud support incredibly our

to strengthen our our while business, foundation term growth for term executing our strategic imperatives growth. continue on We robust long near drive to throughout profitable

significant opportunities in so for XXXX our about We are and even XXXX beyond. excited more and

created have questions. shareholders that people the for XXX,XXX and call Insulet’s improve getting value we're than let’s more open the with operator, for of living lives We started. With diabetes and tremendous just

Operator

Instructions] question [Operator Barclays. will the with of first our And Matt come line from Taylor

Matt Taylor

XXXX XX% question you out that assuming given you've pluses to us estimated XX% to through things you the was, here on but you're the assumptions base, walk XX% and US wanted going last I the got good get of So for you no customer minuses I be start you first some Medicare, some know and that in the the growth and versus some to to year. might where could ask there

Shacey Petrovic

start Sure. you sales and Mike expansion what’s from I'll Matt, factored our guidance. add force. in essentially, the into of But that's the coming investment can maybe,

the XX%. an our footprint United the support driving by we and field made increase about sales benefit. States, certainly XX% staff And that in or investment to So to is

to We terms in access. strides continue of market make

the that doesn't will continue not channel So while drive improved Omnipod. in invest in awareness States then XXXX. we hit it mean to in us the majority we're United impact benefits of to to as education Medicaid that and to in the finally, that And continue XXXX the grow access believe and really to vast access around through and we the coverage Medicare of going in unlock we Medicaid, continue

I’d our say driving States. are things So those the United in three growth

Michael Levitz

this Matt, Mike. is And

definitely the customer you Omnipod -- there our in of business. versus true we’ve in of in those quarter full-year a what indicator the just our as As so It generally is a growth best a that to seasonality US for of as that QX reminder, some be than deductibles surrounds the it deductibles. is guidance, reset base it's that's the is of business, on installed described and mentioned, the it so another the relates business might because basis probably base more but reset really just

And other so not really then their people QX QX. in The resets, purchase indicative deductible fourth the is sometimes, more slower just quarter will QX in dynamic. anything they'll for up than guidance have a pick and that before of

of believe momentum. year, see a the have you the we for it's and very for amount As strong what the we can really gave year tremendous we growth guidance

Matt Taylor

one for you topping other trend in transition? follow-up, help you mentioned there market how internationally specific Can about that is about that dynamics strong maybe from progressing, you and any in up, the a just of aside think think which we France, is should understand you And talk there area real growth the whether us XXXX. the strength whether you was

Shacey Petrovic

Sure.

and And nice so half to say, the strong accounts was about a France and out two business. would for has still seeing market. we're still the a accounts year years to growth And continues -- now very to for be our us. international it for of for started temper, third performer a growth a extraordinary really while I about It of

I years We of down. So still we were tempered sort new little into it would all softening said ago. year. has along we was market along, the of a where couple the said all but last it’s a eventually, say test bit strong, from

Michael Levitz

to Matt, just clarify, where would we be. it It's expected And Mike. this is exactly

expected. we what all is this So

Shacey Petrovic

just bit terms the was about Matt preparation but of transitioning think obviously of team's great European your a existing is focus in for we execution other feel is around you XXXX our we communicate to the which in really our transition, other question the growth. customer tempering factors installed base in or this I why business, wanted see contemplation is then, what continuity little And and on customers,

pricing the fully will growth. to come but market the the international second our uptick we both expect to continue base to going transition, Europe this the despite growth installed and customer half that revenue XXXX, a lot in grow opposed is base in from So as of

Operator

will question Raymond Jayson line from And Bedford next with of our James. come the

Jayson Bedford

stronger question, different guess So was than the I it's benefit in in anticipated user than mix the a the some I base The was the US in geographic to tied and the than competitive the of just had. basis, first the I'm higher bit start thought. quarter we to of guess somewhat implied saw from any wondering US fourth you market. disruption if what I

Shacey Petrovic

huge say outsized. wouldn't I it was see did or benefit. We some

our but have pathways of a our you of then, maybe quarter, that with as know a new patient And in starts upfront transitioning So, really know we Animas significant did don't reminder, any new in cost, no patient I off if access people to were given obviously accounted XX% they XX% for to starts. increase for and drive Omnipod revenue. just max this,

to was growth, of our number quarter installed base certainly added it fronts little States. but United across it a strong So, a the bit a in

Jayson Bedford

then, I expectation a your follow-up four months related guess What as just high the of your three, differed US ago? quarter. you exceeded end the range fourth from for

Michael Levitz

few things. This is A Mike.

dynamic increasing saw Matt’s is, the the their people I is what we reorders things purchase And fourth how of we in the of question amount described product. quarter. saw just One an in of

because things their first that that quarter. do have they higher other or typically because plans maybe planned in deductible deductibles people the reset Sometimes, again like and

than So higher we was what expected. that

higher We base and been than Our guiding installed had customer Shacey growth to expected. as growth described, we our XX%. about of grew XX% what was base

just growth momentum business seeing drove of and terms we tremendous are the -- what the that's that excitement in the and So, of outperformance.

Shacey Petrovic

had to down kind it that's fact reluctant why in Omnipod preceding QX, any Animas, of in new And because quarters. we than patients say to Yeah. of I'm more was to MDI in sort

So, it start have just from a we of quarter strong really was going. standpoint, programs patient that a independent the new

Operator

next Morgan the of Stanley. line And come from Lewis with our David question will

David Lewis

of the and us disruption. you're then up you questions international, your right, quick XX% these the on performance some how the relative about Just how a give thinking greater of couple is and can sense XX% about for and me put to rates themes. sort that growth trend this just that my for a see Shacey, or some to number of XX%, guidance you if international of like year, just underlying there is of underlying thinking France you internationally math

Shacey Petrovic

in on I set I'll about there. maybe of some opportunity Mike the seeing how what we're can certainly let the numbers feel in comment Yeah, and terms specifically color we give market and the

Michael Levitz

Sure.

to time, as quite been been now direct or talking we've some some guidance, contemplate that time relates like the disruption will quite we've of talking there been to that revenue some that short-term our feels around one guidance it for as it we've saying the So is typically be things specific transition volumes about transition is element say growth, we base purchased a we in happen like get as however, this, best that transition some and the the when it market transition the so installed itself one any exits and that to party of there's disruption be another just to indicator related could would enter. this

short that growth factoring just into The occur relate a continues we're to that ’XX. installed just disruption transition, potential robust that we're in the and to so that disruption guidance base short actual be base. could factoring really doesn't the in term the around installed And in term for

Shacey Petrovic

say about that sort is obviously footprint growth in that to -- we're growth new to right to and continued really I and But be the going hope probably a going move you're the looking of of growth make to be did rates of Europe, in at to new it said, markets you're this have ’XX France right entrance think we if we That of we sort I and expansion markets grow outsized able when that we think drive rate once what's beyond how isn't want in market. ballpark in of transition, at ballpark terms of the the so, about to we and we'll that and in truly had, exciting this the global terms continue move market. for into as

David Lewis

and next the about in to your were were better so sort even some business explicit the plan traction for I where quarter, make explicitly forecast? pretty Medicaid already being the commentary is you in US This question And in but that expected, seen same XXXX kind about number really you is just and if than realistic appreciate Animas question of we XXXX, think very you is and the is really clear. I of and fourth not terms think for is the wanted a underlying much then your clear it the Medicare you in -- sure of on that there have in just US how XXXX, you Shacey,

Shacey Petrovic

Medicaid Yeah. in And of terms forecast. Medicaid. expansion Animas and are continued well the The explicitly David, as in our US things both as those of

a despite lot feel the deliver growth expansion that and year. these to But we So hit like going impacts like a really Medicare the fact be big good XXXX. in and is we're despite that, really exciting of about going great XXXX Medicaid us potential that to DASH

Operator

the And of line Weinstein will Mike come our with question next from JPMorgan.

Unidentified Analyst

This Mike. is Robbie in for

thought delivery, in terms saying XXXX. think you a the you’d to and you I give I it in been grow break drug of patient I'll wanted about could because new So adds ask that consistently

profitability going So is of any what as off? in item thinking forward? are about trend the that you there line sales change And the trajectory

Shacey Petrovic

Great.

on business And so we Robbie forecast in is XXXX. in to that base I don't said the Amgen’s think expected What always orders. our ever we we've that, our we said guidance grow and expectations

sort say, that margin and growth terms So headwind really think to the that’s side, see kind of happen is the it how exciting in and It's is successful our the of despite with expansion just in this we me sort the business. that XXXX you because I slight the business which delivery diabetes vast revenue have drug points tremendous drug in diabetes guidance, see delivery, to end of it our to would business, of on Neulasta I but of of majority beyond.

Michael Levitz

is Mike. this Robbie, And

we gross the Just as on our in reduced was it and and what about operations result piece, to referring just, with the target forecast margin business. the with for margin so on just relates question and to Shacey Amgen I internally think your even that expansion team execution mean, even I thrilled we the right positive by are helps XXXX it's are across

deliver are of improvements much the delivery really part for the we smaller shows of that the business strength our so many just overall drug years And operational business is and doing, to it so, to come. a

Unidentified Analyst

won't add revenues patient, can market about there going you similar there and want in XXXX, to something And start it any the you just about to is commercial and a they as revenue thinking to think going a or models people be of metrics size do Medicare forward, follow-up, their any how Medicaid patient to give in forward? people but are terms that per be that should us

Patrick Sullivan

Yeah.

opportunities you take typically we we’ll are similar to be think the that think fair people Medicaid, I the believe were that this D with our are DME in and and As we’ll of that Medicare out about to coverage, believe share population. there that be but able that to we pharmacy rates Medicare Part XXX,XXX Medicaid, for coverage, patient it there when relates

Operator

And the our Kaczor of come next Margaret question line from Blair. will with William

Margaret Kaczor

expected That and you First follow-up one maybe when higher percentage those guys regarding I these of maybe process the conference. could commentary in than to me are day seemed is from referenced you with think it out smooth one? look secondary what was and like on contract contracts come we some Europe. it your What done was distributors intermediaries intermediary really you a that a that, have JPMorgan work

Shacey Petrovic

Yeah. That's exactly right, Margaret.

in have reduce the it So higher and cry it one the the this in than day, jumped because to sure about a -- there's transition. opportunities, transition approach those that's maybe to this we exactly we've is risk that market and complexity on of and more of discovered we're and sort risk we've make for we're been taken thinking key is about learning is the intermediaries And reduce complexity that’s and how team. why mitigate of elements the them reason and percentage so of as rallying every we a mitigate higher of transition the part we

XX% we the business -- were going through intermediaries. estimate talking about last the last of time I think So, the maybe

closer the the flexibility while to And we will. term, XX%. have for XX%, Now, also opportunity the it's that, where long to do we maintaining

but don't is long this reduce complexity term, do risk, in we that. next Europe, will feel that and the just mitigate opportunities our can certainly we X, where XX ham disturb years of So we over in like not opportunities and want we our evidence to X,

Michael Levitz

markets. just add, end would intermediaries increase I in maintain we’re XX% various to the able with even these in pricing the And user

Margaret Kaczor

already change where point this or plus try at out expense folks some of you roll guys you these does to international? it they're have ready Do And into guys your transition, maybe approached structure.

Shacey Petrovic

market. I these expense we just all say conversations on will of I'll the but comment in every let major intermediaries are Mike with across that structure,

Michael Levitz

does our, it And we've expense what from been the really change either not Yeah. the structure guidance or revenue saying.

Margaret Kaczor

different topic. just then a And question, as second

gotten an Or in Medicare of are that within patients before in exceptions related trying of many are pursue any any Medicare, yet how seen change terms to You you formulary. guys attrition you success point? this guidance? these plan? then on patient is mentioned that stories Have on get guys to And you at process in there

Shacey Petrovic

Yeah.

customers for this really some their because who So focused are process. either of opportunity sort but have or the on revenue people exception cash To we use XX folks getting we just customers powders our Medicare good and we're through to questions to a somewhere it's that caution, and exception us, are the exception process. the beneficiary today are support those through XXX secondary out process, pay -- we've we through the team and pocket of insurance a of date, between gotten so not

So a than to get for this of it however, process we and excited to majority this so we're this in we patients they portion right vast and probably our them more we'll our or Medicare thing reimbursed process, general, that absolutely our and do process. help paying is good a get will through through anticipate the through were support potters beneficiary

Operator

with line Canaccord. Rose question And our next Kyle come the of will from

Kyle Rose

we data the are positive. in milestones was So the trial about we remind of process I what saw to think the mean ’XX you regulatory XXXX. question then key IDE just the I could pivotal for and next definitely a and as week project. the eventually eventually Horizon round wanted if ask I us IDE wondered trials about on the last

Shacey Petrovic

Sure.

underway on patient for clinical third still trial the so a out puts is that our track So this We're and lot with the we FDA. IDE plan us that in learning mapped population.

for was to people of our daily did remember, and goal product it's population such and indicated was enough large you injections our a So transition to as able coming from to that with One also be because two component a for things. launch children simple patient was kids multiple to it.

we population. to learning So this IDE in focuses two amount patient a on this and kids age tremendous down are

as make that our pathway we're us. down in all conditions of the through living before kids and this have clinical the we two and so results free way really clinical We so the data, of will to reviewing rest determine age

So no changes today. to guidance

to we move We’re are pre-pivotals. will into this what analysis, once originally outlined, which and if or kind two, of month required any track in before study but other happen we’ll completed I we've determine clinicals on we think next the

may add we we everything in goes it So out. it push studies, to If be want pre-pivotals this well, would year. additional

Kyle Rose

concentrated insulin And then side. question the a similar on

I some should years, commercialization just their in of would guidance very it's I coming in you that XXXX think kind how given about the, U-XXX start we to and at the historically models think, be you’ve point as out on frame market initial how helpful? opportunity, there investors about think thinking

Shacey Petrovic

Sure. obviously. to think is these It's just market and clarify, gets the Yeah. to I programs first partnership in X We're into type excited does come been this us product our big you about a really Kyle, and Lilly terrific market But know with that a but it double U-XXX. way. addressable will

much people to molecules us. it's in then gets So one that's that to opportunity of majority and opportunity, XXXX be insulin That a unmet XXXX growing with type U-XXX, larger dependent a significant for X is living vast and access need, market in will so Lilly’s diabetes. us the of fastest in really come market because which the will but smaller with

Michael Levitz

clarification. And Mike, is this just a

not because It of comes just big to stream. growth the continues market, or the our like accelerate when curve recurring it of revenue to revenue our So for bolus really it's get revenue. a you model, growth

Operator

Cowen. question Doug our will And with of next come Schenkel the line from

Ryan Blicker

This is Ryan for Doug.

Omnipod again XXXX. tailwind it your XXXX about You’ve mix remarks QX how you talk quarter. in the if and and in the this this a benefit past you're benefit business the Did was quarters, as in you cited thinking can prepared few about but material so, over to didn't talk US about, channel how

Michael Levitz

is This Mike.

favorable the that's main of good. It's So, a in the the mix definitely standpoint story. the us continues part pricing to from to be really and not US

in growth growth the As installed by in to that the pretty tracked base, closely the see you revenues. can

primary is installed expect reason but that the trend our the we base. in it continues continue, growth for helpful in growth to be and US to the business So the

Ryan Blicker

color are your are you around that consistent historically? can with they levels about I provide some maybe more where a believe attrition then maybe color, you've a just XXXX do reduce then seen impact asked overall And error know not provide or really there that little can about the is bars earlier Medicare that you help talk on today, a more you and process, in that your attrition XXXX. question material until

Michael Levitz

the question take and attrition the you take rest. This is want to Mike. if I’ll Shacey,

a really to discussions focus installed as our we on moved base, just So customer base. reminder, on

it obviously was and customer ago the additions a so more year patients or the are and contributors reduction in or the think our for -- to I new attrition. base the the of

side data best amount that from a the the on challenges have business. is through we of perspective, you of have that of One that sell because don't the of distributors that we the channel

we between what could or channels. direct So rely the it between channels, on be business. look on can we people move And and it see attrition moving like as not just

very positive. hasn’t about those the with much. expect same. -- aside, The changed So to attrition caveats trend hasn't that is it It we be really seems

we attrition We of because is access us that Medicare continue and are recently to and to. of one the the make to third where our is that's market a cost for other improvements again so until helpful which pathway meaning elements. drives Medicaid their product the of have But of access, patients, Medicare a biggest decision one the the not elements in quality, that is this market had product

we that and Medicare that expansion access really we Medicaid it's kick So go that attrition on saw really XXXX help as the as expect of side, forward we absolutely will broader and in.

Shacey Petrovic

Yeah. that I Mike everything just completely agree said. with

make despite fact we out attrition process, won't product. through attrition. people getting paying the I in are I focused and to that as issues that process exception that are cash the Medicare got with real a really the see that impact think traded some pocket are Medicaid, for solve of this significant the and XXXX exception has a gains driving we year we access on so technically do think of on material they haven't from we've this who potential

Patrick Sullivan

parenthetically will hone I would because certainty. gives our attrition patients the really And add we in opportunity just DASH are on us that where know to the understanding with

Operator

of question will And Jeff line our come Johnson from with next the Baird.

Jeff Johnson

for trying maybe kind XX%; something G&A, of cleaning quarter. was Mike, there? XXXX. in the just to up fourth get OpEx I'm OpEx just up Was from XX%. your to up one jive question guidance there with one-time that XX% XX%, up

Michael Levitz

Well, there weren't any first one-time significant items. of all,

Specifically there ones, are them significant I’ll if call out.

One keep things the to a lot mind is of making European in we're OpEx investments guidance our of the infrastructure. to for relative

that and US of matter. for that for Some manufacturing

the and manned some would And of as majority expect in up as European marketing. of you for G&A are ones from commercial sales the

of year. expenses those for In were I factored OpEx expect there But the ‘XX. will into our to million apart are guidance be So expansion. for there we the $X happen non-recurring prepared year to million That's see, -- first in to that really I incremental items. from mostly material next the European and there that some remarks, my don't that, there half will relative described investments $X non-recurring

Jeff Johnson

X maybe ahead to taking for target things week then delivery question, just so like versus thought up some there are exercise. pre many data that improvement seem my I second guys just interesting to your that XX% basal the you IDE exercise, of range the you with cool especially And can algorithm. like that do XXX in obviously Vienna, saw There last

of all could make maybe and -- Shacey, do kind question all ways in about is, I before could versus you and questions play you guess a to of the in the a your to that approval, trying for get submit a do the you pre-pivotals the sure this you do that. XXXX with how XXXX, all alluded approval ago balance cool end and could to product these more you studies So different this early XXXX, the get you somewhere few by answer question things

balance just do the how to time the market versus stuff? So you cool

Shacey Petrovic

that day. great a our wrestling is Jeff it’s team with question, It's every Yeah. one honestly and

go I right, burden. things think I our all with drive could here you're mantra, of a products value We we technology. back think simplicity could lot amazing which and our reduction and we about do of is to incredible this are --

the where target has adding to the market outcome, simplicity drive that's market really the so of on to ease we user for interface been, if however, we that, easiest time to achieve that or features would and use and functionality don't and populations. we're for including So we're that not focus things, to those of making sure that we where product that compromise but patient we're a a focused on use better with time that's simple, lot compromise on our very market and going do

best is which the So, can first we'll do the we algorithm what a as generation. we've the been very understand data of review doing key all detailed incorporate in along, the strengths fashion, and then in those

they do benefiting we sort out from of market, that ground these even once product seen also technologies I you soon are as learn the get think we're that so lot we before get who about as onto so a to from our there. learn we've we now others experience to our and user us more can, get market can that as want we hovering

Operator

the And Denhoy of with our Raj next question line will from come Jefferies.

Raj Denhoy

Couple PDM? should of year, charging gets from upgrade but we patients revenue the this contribution that approval, a it modeling we you should Will there do it's new that perspective? about going little from for for that? how think be cycle an a on limited you the be later just wanted, launch One about think Will the launch questions. a be when DASH, to know I assuming how

Shacey Petrovic

will any I the for DASH every would accelerate our that's look terms a given piece and goes base revenue to a other of with equipment. just strategy, our to this tremendous quarter we to model in pipeline, as decide amount opportunity and opposed of think or as of piece in and capital never of in at pod in this do a the It's that new what year. an launch product business the installed tied growth commercial volumes product not I and regardless to so drive revenue

Michael Levitz

And this is Mike.

submitted have FDA, it given really the relates guidance, we've we Just the limited it year said, a we a as more model, DASH. of recurring and to this our from benefit is will revenue so as launch revenue XXXX later

Raj Denhoy

to of for? to or just trade But PDM new be XXX,XXX the order buy functionality the can all clear, that get mean in mean their or I globally, I so they a guess to will something new it they patients I PDM is existing DASH have

Shacey Petrovic

working pathways we're They to the from will acquire order be DASH to all have on benefits in to access but to our for PDM get that. DASH, customers a able

Michael Levitz

new launch opportunities. D in coverage And particularly, other of exploring the Medicare light Part

Raj Denhoy

do think do And we existing you to bigger get the have patients a that then one fertile aged you Medicare those Omnipod? think you? think best opportunity. -- is how you that opportunity bigger for Is into just to them otherwise the What's on would keep for in on actually there's that ground the should about it opportunity patients Medicare, population or

Patrick Sullivan

found those We long other they And secondly of Omnipod, opportunities XX would two those it's out are who parts lot were our in attrition the provide keep is and in them that product than period base. those currently time. knew patients. of for an opportunity to customer in they will age are on higher there's because think reluctant the attrition XX a wouldn't for of as a Physicians turning that I patients Medicare paying Medicare of as be patients that them. to the pocket be for are

it's tremendous. the think I then into in both. spillover Medicaid effect is So And

access XXX,XXX to. we opportunity. a have the market now that big all to, of or That's third we didn't the access patients have So,

Operator

will question J.P. come line the Piper And McKim our of from next with Jaffray.

J.P. McKim

I had one Medicare. on

through, like of out volumes. called X have plans you the think I the gone XX% of

already the So them their for gauge those of aids, sponsors, guys just covered on risk pharmacy commercial them not covering? or to trying with X I’m you are so through the

Shacey Petrovic

a It's question. good a mix. It’s Yeah. bit a little of

commercial of So some we sponsors. coverage those the have do side on plan with

you with on specific a I policies their fully plan process, are we just to if couldn’t all I not discussions guidance coverage the today, will successful in of them of going them but to by We these that with October. of number think be a are sponsors, understand of them. give and anticipate determine all that most

were before good life we're to Omnipod to them. successful how beneficiary QX, these and able Medicare guidance give for going you we establishing accessing So on be probably really

So we'll with posted, we have already but of of all in them. discussions some today with we're commercial certainly and you keep coverage them

J.P. McKim

think ’XX. And guided then XX% margins, one mean on I to I gross for you XX%

plan growth? the that at mix from your we you frame Is coming up? new to XX%, kind that overall good in direct of a about way ramp think here there more how versus volume As to just should US

Michael Levitz

This is Mike.

So it benefit. first gave half two the the to that the tale year, halves all of it's to of second guidance because half is full really the we related almost is the interesting, is Europe for this a second half investment year, and for in

by rate XXX So margin half the on in improved the run second basis gross points.

in coming my out So, going XX%, what prepared half range. the be remarks that what is said of second XX% to I we're saying -- we're in the

manufacturing that as the XX, We that US quite of US manufacturing. nicely. So drive relates of to definitely will it down expect cost before the is all target

just our out those were supply of When ahead chain improvements drivers and margin us. gross about the largely and it's remain Day laid Investor So principal still we the expansion, drivers of not manufacturing volumes. improvements at

comes a freight basis we're past, combination half But as the point improvement supply in the up we really even from add we've this So, top. XX like of on they continued areas, of support rate and the the XXX on in volume in really really past number chain about focus quickly. then small, mundane ones as talked making seem pennies improvements may and improvements of but the by that's the the manufacturing Europe but year, back in to XX% driven manufacturing, in US going and of run is reflected second the XX% that

Operator

of with Leerink will And Danielle come our Partners. next question the from line Antalffy

Danielle Antalffy

type a the to pumps population but has a question specifically Xs we're Shacey, had hearing you portion XX% we like diabetes pancreas for positive about in that call of penetration just something, national on to XX% Insulet, we you for commentary drug while for the to pump little and XX% have pretty TAM something mentioned the the pediatric artificial do a also hosted the what about that leaving something average. as back for or could the the penetrative aside, versus delivery XX% think business,

So that number XX% age. higher, as minus albeit those inherently, that should would move imply that attrition some to XX%

to surprised say you I market market? potential there? second pancreas the Xs? products my the are number I second get was view part of is in on then And I could what So just think XX% that the type question is important this do actually part the number long-term type X. am we penetration X was have to artificial Xs. your how hear the curious of And type pump to call move the for to that is then question that of on on patients Omnipod What and same type once

Shacey Petrovic

ones. good really are both think I

probably we You're X the to you actually look in right. today XX% when States, example. Europe type penetration somewhere When smaller in aggregate, for when pump about the the diabetes across globe XX% use living between are and closer much rates of on and therapy XX% pump United with people

markets of opportunity grow. to the for lots So

around around suggest somewhere a and CAGR. that growing States CAGR Our growing data Europe, is it's the United in would that market somewhere a X% in X%

areas and I with So where the have you typically -- because highly of comfortable people think refer just is way want pump pediatric revert markets that's patients to if where once you technologies the familiar will more reason advantages. are I think the the injections, you -- expanding. where I unlikely therapy, think see this could to And get are I we both with adopt the and that all pediatrics it’s then and back more the because these good indicator because go,

this time, continue market over think accelerate. I will to So

therapy is pumps. technologies drive customers injections. XX% I of helping But penetration clearly that multiple pump of because there, from daily our AP think from and all to CGM goes coming a are contributor Omnipod are to patch to huge

will data. don't driving well ownership although clearly and doubt we as obviously great true to take overall the a our without have of pump likely market. that business. of visibility And and the in kind we the it's as so ground That's That feet true change in Europe States in on growth that United very yet to get we're start

what attention tremendous excited type population, of of amount part has patient that make patient of factors work it for with got the XX% can understand get them. to doing today but that, our I like reasons, X that that X to insulin are better needs think us value to of I that think to manufacturers a haven’t The does And it's of that second population experience question, sort do for potential that look as today for programs a area population. really patient of human and an we're about concentrated your and great we've growing drive dependent we what we're because type a doing the of research we variety about unlock paid understanding that population and Omnipod help that interface and to user insulin because our that lot really is a tremendous need users

as current see opportunity. of these as we're and in type think two I is really -- acceleration markets those to going So products opportunity X the big the that launch with that is just

Operator

Patrick to time. questions Sullivan. would I the this I'm conference at back turn showing like to you. Thank no further now

Patrick Sullivan

coverage, much. Thank their diseases. employees improving thrilled manufacturing with us of the operation continuing call. Thank Insulet and easing significant burden commitment quarter of of to and ground CMS with breaking you you accomplishments. US the performance. our for work the forward you, for and first company submission the very DASH, four delivering XXXX, living operator. a am to of other on I the deliver on thank very on like to strong direct joining we I’d hard speaking absolutely Thank and with in people conference and today to diabetes the call our look lives you plan performance go on Europe, in spectacular the implementation to and

Operator

you a Ladies and Thank gentlemen, for wonderful have participation this your and conference. day. today's concludes

You may all disconnect.

Insulet (PODD) 21 Feb 182017 Q4 Earnings call transcript